Ho Sung Kang

Ho Sung Kang

Auto-generated profile, based on publicly available information

Ho Sung Kang

Department of Molecular Biology, College of Natural Sciences, Pusan National University, Pusan 609-735, Republic of Korea

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2017 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SLSu Yeon Lee
Su Yeon Lee
EJEui Kyong Jeong
Eui Kyong Jeong
MJMin Kyung Ju
Min Kyung Ju
HJHyun Min Jeon
Hyun Min Jeon
MKMin Young Kim
Min Young Kim
HKHo Sung Kang
Ho Sung Kang
Radiation therapy is one of the major tools of cancer treatment, and is widely used for a variety of malignant tumours. Radiotherapy causes DNA damage directly by ionization or indirectly via the generation of reactive oxygen species (ROS), thereby destroying cancer cells. However, ionizing radiation (IR) paradoxically promotes metastasis and invasion of cancer cells by inducing the epithelial-mesenchymal transition (EMT). Metastasis is a major obstacle to successful cancer therapy, and is closely linked to the rates of morbidity and mortality of many cancers. ROS have been shown to play important roles in mediating the biological effects of IR. ROS have been implicated in IR-induced EMT, via activation of several EMT transcription factors—including Snail, HIF-1, ZEB1, and STAT3—that are activated by signalling pathways, including those of TGF-β, Wnt, Hedgehog, Notch, G-CSF, EGFR/PI3K/Akt, and MAPK. Cancer cells that undergo EMT have been shown to acquire stemness and undergo metabolic changes, although these points are debated. IR is known to induce cancer stem cell (CSC) properties, including dedifferentiation and self-renewal, and to promote oncogenic metabolism by activating these EMT-inducing pathways. Much accumulated evidence has shown that metabolic alterations in cancer cells are closely associated with the EMT and CSC phenotypes; specifically, the IR-induced oncogenic metabolism seems to be required for acquisition of the EMT and CSC phenotypes. IR can also elicit various changes in the tumour microenvironment (TME) that may affect invasion and metastasis. EMT, CSC, and oncogenic metabolism are involved in radioresistance; targeting them may improve the efficacy of radiotherapy, preventing tumour recurrence and metastasis. This study focuses on the molecular mechanisms of IR-induced EMT, CSCs, oncogenic metabolism, and alterations in the TME. We discuss how IR-induced EMT/CSC/oncogenic metabolism may promote resistance to radiotherapy; we also review efforts to develop therapeutic approaches to eliminate these IR-induced adverse effects.

31 January 2018 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
SLSu Yeon Lee
Su Yeon Lee
MJMin Kyung Ju
Min Kyung Ju
HJHyun Min Jeon
Hyun Min Jeon
EJEui Kyong Jeong
Eui Kyong Jeong
YLYig Ji Lee
Yig Ji Lee
HKHo Sung Kang
Ho Sung Kang
Rapidly growing malignant tumors frequently encounter hypoxia and nutrient (e.g., glucose) deprivation, which occurs because of insufficient blood supply. This results in necrotic cell death in the core region of solid tumors. Necrotic cells release their cellular cytoplasmic contents into the extracellular space, such as high mobility group box 1 (HMGB1), which is a nonhistone nuclear protein, but acts as a proinflammatory and tumor‐promoting cytokine when released by necrotic cells. These released molecules recruit immune and inflammatory cells, which exert tumor‐promoting activity by inducing angiogenesis, proliferation, and invasion. Development of a necrotic core in cancer patients is also associated with poor prognosis. Conventionally, necrosis has been thought of as an unregulated process, unlike programmed cell death processes like apoptosis and autophagy. Recently, necrosis has been recognized as a programmed cell death, encompassing processes such as oncosis, necroptosis, and others. Metabolic stress‐induced necrosis and its regulatory mechanisms have been poorly investigated until recently. Snail and Dlx‐2, EMT‐inducing transcription factors, are responsible for metabolic stress‐induced necrosis in tumors. Snail and Dlx‐2 contribute to tumor progression by promoting necrosis and inducing EMT and oncogenic metabolism. Oncogenic metabolism has been shown to play a role(s) in initiating necrosis. Here, we discuss the molecular mechanisms underlying metabolic stress‐induced programmed necrosis that promote tumor progression and aggressiveness.

1 January 2005 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
HPH. G. Park
H. G. Park
SHS. I. Han
S. I. Han
SOS. Y. Oh
S. Y. Oh
HKH. S. Kang
H. S. Kang

11 January 2016 in Oncotarget
Verified
Journal Article
Open access
SLSu Yeon Lee
Su Yeon Lee
HJHyun Min Jeon
Hyun Min Jeon
MJMin Kyung Ju
Min Kyung Ju
EJEui Kyong Jeong
Eui Kyong Jeong
CKCho Hee Kim
Cho Hee Kim
HKHo Sung Kang
Ho Sung Kang
Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch

1 January 2018 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
SLSu Yeon Lee
Su Yeon Lee
MJMin Kyung Ju
Min Kyung Ju
HJHyun Min Jeon
Hyun Min Jeon
YLYig Ji Lee
Yig Ji Lee
CKCho Hee Kim
Cho Hee Kim
HKHo Sung Kang
Ho Sung Kang
Metastasis is a major obstacle to the efficient and successful treatment of cancer. Initiation of metastasis requires epithelial‐mesenchymal transition (EMT) that is regulated by several transcription factors, including Snail and ZEB1/2. EMT is closely linked to the acquisition of cancer stem cell (CSC) properties and chemoresistance, which contribute to tumor malignancy. Tumor suppressor p53 inhibits EMT and metastasis by negatively regulating several EMT‐inducing transcription factors and regulatory molecules; thus, its inhibition is crucial in EMT, invasion, metastasis, and stemness. Metabolic alterations are another hallmark of cancer. Most cancer cells are more dependent on glycolysis than on mitochondrial oxidative phosphorylation for their energy production, even in the presence of oxygen. Cancer cells enhance other oncogenic metabolic pathways, such as glutamine metabolism, pentose phosphate pathway, and the synthesis of fatty acids and cholesterol. Metabolic reprogramming in cancer is regulated by the activation of oncogenes or loss of tumor suppressors that contribute to tumor progression. Oncogenic metabolism has been recently linked closely with the induction of EMT or CSC phenotypes by the induction of several metabolic enzyme genes. In addition, several transcription factors and molecules involved in EMT or CSCs, including Snail, Dlx‐2, HIF‐1α, STAT3, TGF‐β, Wnt, and Akt, regulate oncogenic metabolism. Moreover, p53 induces metabolic change by directly regulating several metabolic enzymes. The collective data indicate the importance of oncogenic metabolism in the regulation of EMT, cell invasion and metastasis, and adoption of the CSC phenotype, which all contribute to malignant transformation and tumor development. In this review, we highlight the oncogenic metabolism as a key regulator of EMT and CSC, which is related with tumor progression involving metastasis and chemoresistance. Targeting oncometabolism might be a promising strategy for the development of effective anticancer therapy.

3 July 2019 in Molecular Medicine Reports
Verified
Journal Article
Closed access
PDF file
SLSu Yeon Lee
Su Yeon Lee
MJMin Kyung Ju
Min Kyung Ju
HJHyun Min Jeon
Hyun Min Jeon
YLYig Ji Lee
Yig Ji Lee
CKCho Hee Kim
Cho Hee Kim
HKHo Sung Kang
Ho Sung Kang
Reactive oxygen species (ROS) are important cellular second messengers involved in various aspects of cell signaling. ROS are elevated in multiple types of cancer cells, and this elevation is known to be involved in pathological processes of cancer. Although high levels of ROS exert cytotoxic effects on cancer cells, low levels of ROS stimulate cell proliferation and survival by inducing several pro‑survival signaling pathways. In addition, ROS have been shown to induce epithelial‑mesenchymal transition (EMT), which is essential for the initiation of metastasis. However, the precise mechanism of ROS‑induced EMT remains to be elucidated. In the present study, it was indicated that ROS induce EMT by activating Snail expression, which then represses E‑cadherin expression in MCF‑7 cells. It was further indicated that distal‑less homeobox‑2 (Dlx‑2), one of the human Dlx gene family proteins involved in embryonic development, acts as an upstream regulator of ROS‑induced Snail expression. It was also revealed that ROS treatment induces the glycolytic switch, a phenomenon whereby cancer cells primarily rely on glycolysis instead of mitochondrial oxidative phosphorylation for ATP production, even in the presence of oxygen. In addition, ROS inhibited oxidative phosphorylation and caused cytochrome c oxidase inhibition via the Dlx‑2/Snail cascade. These results suggest that ROS induce EMT, the glycolytic switch and mitochondrial repression by activating the Dlx‑2/Snail axis, thereby playing crucial roles in MCF‑7 cancer cell progression.